NASDAQ:INVA Innoviva (INVA) Stock Price, News & Analysis $20.03 +0.19 (+0.96%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$20.57 +0.54 (+2.70%) As of 08/28/2025 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Innoviva Stock (NASDAQ:INVA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Innoviva alerts:Sign Up Key Stats Today's Range$19.60▼$20.0650-Day Range$18.17▼$21.0052-Week Range$16.67▼$22.00Volume510,842 shsAverage Volume820,988 shsMarket Capitalization$1.26 billionP/E Ratio64.61Dividend YieldN/APrice Target$42.75Consensus RatingBuy Company Overview Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. Read More Innoviva Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreINVA MarketRank™: Innoviva scored higher than 90% of companies evaluated by MarketBeat, and ranked 124th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingInnoviva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInnoviva has only been the subject of 3 research reports in the past 90 days.Read more about Innoviva's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth369.70% Earnings GrowthEarnings for Innoviva are expected to grow by 369.70% in the coming year, from $0.33 to $1.55 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Innoviva is 64.61, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.18.Price to Earnings Ratio vs. SectorThe P/E ratio of Innoviva is 64.61, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.56.Price to Book Value per Share RatioInnoviva has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Innoviva's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.56% of the float of Innoviva has been sold short.Short Interest Ratio / Days to CoverInnoviva has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.Change versus previous monthShort interest in Innoviva has recently decreased by 2.42%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInnoviva does not currently pay a dividend.Dividend GrowthInnoviva does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-0.33 Percentage of Shares Shorted15.56% of the float of Innoviva has been sold short.Short Interest Ratio / Days to CoverInnoviva has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.Change versus previous monthShort interest in Innoviva has recently decreased by 2.42%, indicating that investor sentiment is improving. News and Social Media4.0 / 5News Sentiment1.27 News SentimentInnoviva has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Innoviva this week, compared to 4 articles on an average week.Search Interest8 people have searched for INVA on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Innoviva to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Innoviva insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.25% of the stock of Innoviva is held by insiders.Percentage Held by Institutions99.12% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Innoviva's insider trading history. Receive INVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INVA Stock News HeadlinesInnoviva to Participate in Upcoming Investor ConferencesAugust 26 at 7:11 AM | mms.businesswire.comPromising Outlook for Theravance Biopharma: Buy Rating Backed by Phase 3 CYPRESS Trial DevelopmentsAugust 26 at 6:10 AM | tipranks.comAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation. | Paradigm Press (Ad)Theravance Completes Enrollment in Phase 3 CYPRESS StudyAugust 25, 2025 | tipranks.comInnoviva (NASDAQ:INVA) Lowered to Buy Rating by Wall Street ZenAugust 25, 2025 | americanbankingnews.comInnoviva (NASDAQ:INVA) Stock Rating Upgraded by Wall Street ZenAugust 18, 2025 | americanbankingnews.comThere May Be Some Bright Spots In Innoviva's (NASDAQ:INVA) EarningsAugust 14, 2025 | uk.finance.yahoo.comTheravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ...August 13, 2025 | gurufocus.comSee More Headlines INVA Stock Analysis - Frequently Asked Questions How have INVA shares performed this year? Innoviva's stock was trading at $17.35 on January 1st, 2025. Since then, INVA shares have increased by 15.4% and is now trading at $20.03. How were Innoviva's earnings last quarter? Innoviva, Inc. (NASDAQ:INVA) released its quarterly earnings results on Wednesday, August, 6th. The biotechnology company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.20. The biotechnology company earned $100.28 million during the quarter, compared to analyst estimates of $87.10 million. Innoviva had a trailing twelve-month return on equity of 18.67% and a net margin of 10.44%. Who are Innoviva's major shareholders? Top institutional investors of Innoviva include Franklin Resources Inc. (4.50%), American Century Companies Inc. (3.29%), Systematic Financial Management LP (3.28%) and Arrowstreet Capital Limited Partnership (2.72%). View institutional ownership trends. How do I buy shares of Innoviva? Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Innoviva own? Based on aggregate information from My MarketBeat watchlists, some other companies that Innoviva investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Visa (V). Company Calendar Last Earnings8/06/2025Today8/28/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Large Cap Pharma Sub-IndustryBiotechnology Current SymbolNASDAQ:INVA Previous SymbolNASDAQ:THRX CIK1080014 Webwww.inva.com Phone(650) 238-9600Fax650-827-8690Employees100Year Founded1996Price Target and Rating Average Price Target for Innoviva$42.75 High Price Target$55.00 Low Price Target$26.00 Potential Upside/Downside+113.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)$0.31 Trailing P/E Ratio64.61 Forward P/E Ratio60.70 P/E GrowthN/ANet Income$23.39 million Net Margins10.44% Pretax Margin17.71% Return on Equity18.67% Return on Assets9.92% Debt Debt-to-Equity Ratio0.36 Current Ratio2.64 Quick Ratio2.44 Sales & Book Value Annual Sales$358.71 million Price / Sales3.52 Cash Flow$3.46 per share Price / Cash Flow5.79 Book Value$11.34 per share Price / Book1.77Miscellaneous Outstanding Shares63,020,000Free Float61,603,000Market Cap$1.26 billion OptionableOptionable Beta0.38 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:INVA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innoviva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.